Zydus Lifesciences informs about press release

28 May 2025 Evaluate
Zydus Lifesciences has informed that it enclosed a copy of press release dated May 28, 2025, titled ‘Zydus receives USFDA ‘Fast Track Designation’ for Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of Amyotrophic Lateral Sclerosis (ALS)’. The contents of the press release give full details. 

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

883.85 7.75 (0.88%)
22-Jan-2026 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.25
Dr. Reddys Lab 1220.20
Cipla 1374.60
Zydus Lifesciences 883.85
Lupin 2165.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×